Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
about
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of ageAntiretroviral therapy for HIV-infected childrenHigh drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in SpainFactors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review.Getting to 90-90-90 in paediatric HIV: What is needed?Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South AfricaPharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trialHigh survival and treatment success sustained after two and three years of first-line ART for children in Cambodia.Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a review of published clinical studiesMonitoring Antiretroviral Therapy in HIV-Infected Children in Resource-Limited Countries: A Tale of Two EpidemicsEnhancing psychosocial support for HIV positive adolescents in Harare, Zimbabwe.When masculinity interferes with women's treatment of HIV infection: a qualitative study about adherence to antiretroviral therapy in ZimbabwePulmonary Arterial Hypertension among HIV-Infected Children: Results of a National Survey and Review of the LiteratureEarly response to highly active antiretroviral therapy in HIV-1-infected Kenyan children.Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenBuilding adherence-competent communities: factors promoting children's adherence to anti-retroviral HIV/AIDS treatment in rural Zimbabwe.Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy.A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa.Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Antiretroviral therapy for children: challenges and opportunities.Relationship between viral load and behavioral measures of adherence to antiretroviral therapy in children living with human immunodeficiency virus in Latin AmericaFrequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time.Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children.Pharmacotherapy of pediatric and adolescent HIV infection24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.Management of paediatric HIV-1 resistance.Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatmentEffectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectionMolecular HIV screening.CD4-gp120 interaction interface - a gateway for HIV-1 infection in human: molecular network, modeling and docking studies.Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.Clinical markers of immunodeficiency and mechanism of immune reconstitution inflammatory syndrome and highly active antiretroviral therapy on HIV: workshop 3A.
P2860
Q24202004-48D85DF6-1B03-4B70-9B14-FC3FC7124B09Q24247327-118B406E-1B6B-45DC-9A32-B69E442DFAF6Q28484394-9603DDDA-5FD8-4E00-9F96-C295823E9990Q30371970-D0B582C9-B248-44FC-BE4E-FCA5BEC5D43CQ30385352-D8BDED26-9546-42C1-8B40-18997F9954F6Q30539434-6615F66D-07CA-423A-9BD6-C04C9444DDA4Q33279183-FA5F1C9F-246D-471C-B61C-7262DF7FFF01Q33765130-F0CD3F60-A1A3-47E8-8EAE-7801F05228A7Q33776928-171A917D-54DC-4D84-BF5E-60A976141431Q33972150-576AFD95-DAF9-4B93-9E8F-C5741A5BE0A5Q34045390-D79A3CF0-8B96-4B23-815F-A82799D363CDQ34077658-B45A974F-6BDA-461C-804F-0D673DCA46F5Q34358076-AF66AD7E-DEC9-4405-934C-306D1283275EQ34734797-B96EB0B1-563D-461E-81ED-3C3603D6EE3BQ34875901-9C005E4E-16BE-49B2-8AAE-3149D079F07FQ35081250-873A0E86-5539-4DCF-A814-4D78F9AB1685Q35296597-3A8C8A2F-08C6-4BB2-B79A-60D9D815B2FEQ36048997-BCE230FD-9B17-44F3-8B18-5DE7FB61AD1DQ36154492-ACDFBDA5-4483-4C9E-873A-007C7B4A7518Q36349683-26775E64-A38F-4B50-AE73-8072F7FD39ACQ36439546-1EB41BCD-45BD-4D79-8D00-37BDF89B78C8Q36465148-04FB5379-F1FE-4AF9-BD40-AA6F93B94D7FQ36488965-74B59317-1F53-4003-A7F3-DB85E2AF0DABQ36779718-1A8518FC-89BC-479C-8A39-080D295C46EFQ36806770-17FE348B-E214-47B2-9216-5BABCE7938DDQ37015463-DF1792DA-A047-43AD-B3CB-77D412C769D7Q37057964-7CF14A12-4830-4CAF-8395-8FA2C2E1C58DQ37156124-DF643BC6-3DEC-4040-9EEE-7C2355D57746Q37240305-1EC8D071-A0C7-4677-A034-D21F825746D7Q37299209-65877AE4-82AF-40CC-B073-9225E75E9DB1Q37326138-126F5490-733C-4EB9-AEB8-5329DBEFF6F7Q37392730-D1220F7F-1B4A-4BD0-814D-44B9C187D763Q37455795-06F36F78-C75C-4922-85DC-D84DED3EB882Q37461250-438647EA-3BA7-4313-BA13-E4F4ABEB846BQ37465373-75371E79-5339-4A7D-BEEB-4C52D01A4E88Q37696892-971BB653-DDD5-47BE-B524-EA4396758992Q38142249-4290E8A5-B6B7-46F0-87CC-048F3FC7001CQ38377965-74FF6AFA-3E9E-4293-B3EB-B7D434D9062EQ38472689-B2D81401-314E-40B2-B044-D3AAD9D70EFFQ39767247-106325D4-7DAB-490E-86B3-24AC2391FA4B
P2860
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@ast
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@en
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@nl
type
label
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@ast
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@en
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@nl
prefLabel
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@ast
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@en
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@nl
P2093
P1476
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
@en
P2093
Annemarie M C van Rossum
Pieter L A Fraaij
Ronald de Groot
P304
P356
10.1016/S1473-3099(02)00183-4
P577
2002-02-01T00:00:00Z